Valneva SE Logo

Valneva SE

Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.

VLA | PA

Overview

Corporate Details

ISIN(s):
AT0000A10B99 (+3 more)
LEI:
969500DIVIP5VKNW4948
Country:
France
Address:
6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company leverages its expertise to manage a portfolio of commercialized vaccines, including a single-shot vaccine for chikungunya, and to advance a clinical pipeline of candidates. Key development programs target diseases such as Lyme disease, Shigella, and Zika.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 17:35
Capital/Financing Update
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de P…
French 202.1 KB
2025-10-06 17:35
Capital/Financing Update
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advis…
English 212.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du v…
French 218.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccin…
English 222.5 KB
2025-07-11 17:35
Regulatory News Service
Valneva annonce la levée de la restriction temporaire de l'Agence européenne de…
French 165.8 KB
2025-07-11 17:35
Regulatory News Service
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction …
English 208.0 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva annonce l’approbation des résolutions présentées à son Assemblée Généra…
French 145.4 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY…
English 119.4 KB
2025-06-05 17:45
Earnings Release
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance…
French 236.5 KB
2025-06-05 17:45
Earnings Release
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Resu…
English 178.3 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025
French 160.2 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Declaration of shares and voting rights - May 2025
English 170.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva annonce la mise à disposition des documents préparatoires à son Assembl…
French 115.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva Announces Availability of Documentation for its Combined Shareholder Me…
English 122.8 KB
2025-05-26 17:30
Regulatory News Service
Valneva participera à différentes conférences d’investisseurs aux États-Unis et…
French 150.8 KB

Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valneva SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-18 N/A Other Buy 44,222 N/A
2024-01-03 N/A Other Other 34,802 N/A
2023-06-20 N/A Other Sell 192,547 1,406,228.50 EUR
2023-06-19 N/A Other Sell 30,661 209,629.26 EUR
2023-06-16 N/A Other Sell 85,589 582,493.06 EUR
2023-06-15 N/A Other Sell 28,179 189,503.78 EUR
2023-06-14 N/A Other Sell 228,951 1,519,914.11 EUR
2023-06-13 N/A Other Sell 29,401 187,922.37 EUR
2023-06-12 N/A Other Sell 117,854 733,782.57 EUR
2023-05-10 N/A Other Buy 87,523 N/A

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.